Johnson & Johnson (JNJ) Pushes Higher on Solid Results; Stock Moves Above 200 Day MA

Leerink Partners Raises Price Target on Johnson & Johnson (JNJ) Following 4Q Earnings

January 27, 2016 7:31 AM EST

Leerink Partners reiterated an Outperform rating on Johnson & Johnson (NYSE: JNJ), and raised the price target to $120.00 (from $115.00), following the company's 4Q earnings report. JNJ's 2015 EPS benefitted meaningfully from higher other income tied to divestitures. 2016 EPS estimate moves to $6.50 (+5%) from $6.40 previously, with better operating leverage and lower share count through buybacks offsetting ramping FX headwinds.

Analyst Danielle Antalffy... More

J&J profit beats forecasts, helped by lower taxes, cost cuts

January 26, 2016 6:51 AM EST

By Ransdell Pierson

(Reuters) - Johnson & Johnson (NYSE: JNJ) on Tuesday reported higher-than-expected quarterly earnings, helped by cost cuts and lower taxes, and gave a 2016 profit outlook slightly above Wall Street's.

Shares of the diversified healthcare company rose almost 5 percent to $101.18 as investors shrugged off fourth-quarter sales and a 2016 revenue outlook that were both below analysts' estimates.

Edward Jones analyst Ashtyn Evans said investors were cheered by J&J's vow to make more of its medical devices market leaders and to launch 30 new devices this year, including a new insulin pump.

... More

Johnson & Johnson (JNJ) Tops Q4 EPS by 2c

January 26, 2016 6:41 AM EST

Johnson & Johnson (NYSE: JNJ) reported Q4 EPS of $1.44, $0.02 better than the analyst estimate of $1.42. Revenue for the quarter came in at $17.8 billion versus the consensus estimate of $17.88 billion.

"Johnson & Johnson delivered strong underlying growth in 2015, driven by the performance of our Pharmaceutical business and iconic Consumer brands," said Alex Gorsky, Chairman and Chief Executive Officer. "As we enter 2016, our core business is very healthy, and the recent decisive actions we've taken in support of each of our businesses position us well to drive sustainable long-term growth, faster than the markets we... More